CNS disorders are now being reclassified by molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological upgrade; it is a strategic reset. Sponsors who continue to build programs around blunt diagnostic categories and legacy endpoints will increasingly fail, not because their science is weak, but because their development logic is obsolete.